Treatment of an obese diabetic

Česká verzia

Authors: Š. Svačina
Authors place of work: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MU Dr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2010; 56(10): 1078-1081
Category: Obesity 2010

Summary

Weight reduction is an important component of comprehensive management of diabetes. Weight reduction can be achieved using 6 methods: 1. diet 2. physical activity, 3. psychotherapy, 4. bariatric surgery, 5. pharmacotherapy of obesity, 6. selection of an appropriate antidiabetic medication. Orlistat is the only antiobesity agent presently available in the Czech Republic. Weight neutral (metformin and gliptins) and weight reducing antidiabetics (incretine analogues exenatide and liraglutide) and insulin analogue detemir are suitable antidiabetic drugs. We thus have a sufficient range of options available for weight reduction in diabetic patients.

Key words:
obesity – diet therapy – bariatric surgery – antiobesity medication – liraglutid – exenatid – levemir – metformin

Zdroje

1. Lean ME, Powrie JK, Anderson AS et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228– 233.

2. Fried M, Svačina Š, Owen K. Bariatrická chirurgie a diabetes. Trendy v diabetologii 10. Praha: Galén 2005.

3. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta‑analysis. Am J Med 2009; 122: 248– 256.

4. Svačina Š et al. Klinická dietologie. Praha: Grada 2008.

5. Regensteiner JG, Reusch JE, Stewart KJ et al. Exercise and Diabetes. New York: Humana Press 2009.

6. Svačina Š. Obezita a diabetes. Praha: Maxdorf 2000.

7. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994– 1003.

8. Šmahelová A. Výsledky multicentrického sledování léčby sibutraminem u obézních diabetiků v České republice. Vnitř Lék 2005; 51: 676– 680.

9. Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over- the-counter dosage. Expert Opin Pharmacother 2007; 8: 1733– 1742.

10. Svačina Š. Prevence diabetu a jeho komplikací. Praha: Triton 2008.

11. Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753– 759.

12. Svačina Š. Systémové účinky metforminu. Postgrad Med 2010.

13. Martin S, Kolb H, Beuth J et al. Change in patients’ body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003; 46: 1611– 1617.

14. Plank J, Bodenlenz M, Sinner F et al. A double‑blind, randomized, dose‑response study investigating the pharmacodynamic and pharmacokinetic properties of the long‑acting insulin analog detemir. Diabetes Care 2005; 28: 1107– 1112.

15. Svačina Š et al. Metabolický syndrom. Praha: Triton 2006.

16. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007; 9: 31– 38.

17. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá Fronta 2010.

18. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275– 286.

19. Bhushan R, Elkind‑ Hirsch KE, Bhushan M et al. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr Pract 2008; 14: 993– 999.

20. Astrup A, Rössner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double‑blind, placebo- controlled study. Lancet 2009; 374: 1606– 1616.

21. Svačina Š. Potenciální nová antidiabetika v příštím desetiletí. Vnitř Lék 2009; 55: 429– 433.